Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrochlorothiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.97 |
| ▸ | CA2 | P00918 | 5/20 | 0.97 |
| ▸ | CA1 | P00915 | 5/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 2/20 | 0.97 |
| ▸ | APEX1 | P27695 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | CA12 | O43570 | 5/20 | 0.68 |
| ▸ | CA9 | Q16790 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochlorothiazide SCHEMBL156490 | 0.99 | LMNA (1.00) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL9349 | 0.99 | LMNA (1.00) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL29366243 | 0.99 | LMNA (1.00) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27674482 | 0.97 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL9508286 | 0.97 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL10778059 | 0.97 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL10408471 | 0.97 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27992968 | 0.97 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27630714 | 0.97 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL5929409 | 0.97 | LMNA (0.97) | LMNACA2CA1CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080433-A1 | METAL COORDINATED COMPOSITIONS | SYNTHONICS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130184447-A1 | METAL COORDINATED COMPOSITIONS | SYNTHONICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8389726-B2 | Metal coordinated compositions | SYNTHONICS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110275792-A1 | METAL COORDINATED COMPOSITIONS | SYNTHONICS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-7989440-B2 | Metal coordinated compositions | SYNTHONICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7799937-B2 | Metal coordinated compositions | SYNTHONICS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090143338-A1 | Metal coordinated compositions | PICCARIELLO THOMAS | 2009-06-04 | — | — | US | disclosed |
| EP-1945191-A2 | METAL COORDINATED COMPOSITIONS | Synthonics, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080015352-A1 | Metal coordinated compositions | HTERT3, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007050181-A2 | METAL COORDINATED COMPOSITIONS | SYNTHONICS, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060141054-A1 | Metal coordinated compositions | SYNTHONICS, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015352-A1 | Metal coordinated compositions | SLC30A6, SLC39A7, SLC39A14 | LMNA 4261/4885CA2 177/4885CA1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.